Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.47 USD | -0.55% | -1.29% | +6.81% |
Apr. 04 | Boston Scientific, Axonics Receive FTC Second Request on Merger Deal | MT |
Apr. 04 | Boston Scientific, Axonics Merger Prompts FTC to Request Additional Information | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 131.88 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.81% | 3.39B | C- | ||
+11.84% | 127B | A- | ||
-8.69% | 10.68B | A- | ||
-1.71% | 8.59B | C | ||
+14.99% | 7.09B | C | ||
+27.16% | 5.07B | B+ | ||
-0.98% | 3.04B | B- | ||
-13.77% | 2.02B | - | - | |
-9.83% | 2B | - | ||
-27.30% | 1.69B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AXNX Stock
- Ratings Axonics, Inc.